Literature DB >> 18625650

Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases.

I Cavazzana1, A Ceribelli, M Quinzanini, M Scarsi, P Airò, R Cattaneo, F Franceschini.   

Abstract

We retrospectively analysed the prevalence and clinical features associated to anti-Ku antibodies in patients affected by different autoimmune diseases. Anti-Ku antibodies are detected in 147 sera out of 7239 anti-ENA positive sera (2%). They are found in 2% of patients with systemic sclerosis (SSc) (8 out of 379), 1.8% of systemic lupus erythematosus (SLE) (7 out of 372) and 1.8% of undifferentiated connective tissue disease (UCTD) (9 out of 496) and more rarely in Sjögren Syndrome and rheumatoid arthritis. Most of anti-Ku positive patients were affected by UCTD and overlap syndromes, including polymyositis, SSc and SLE. Interstitial lung disease, myositis, articular symptoms, Raynaud's phenomenon and sicca represents the main clinical features detected in our cohort. The rate and severity of pulmonary disease is similar to those found in other SSc patients. Isolated anti-Ku were detected in about 47% of sera. No clinical differences were observed between these patients and subjects with multiple anti-nuclear specificities. However, anti-Ku are usually detected in association with other serological markers in SLE and Sjögren Syndrome, while they occurred isolated in SSc and polymyositis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625650     DOI: 10.1177/0961203308089442

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  20 in total

1.  Facial nerve palsy and anti-Ku autoantibodies.

Authors:  Raoul Sutter; Bernard Mengiardi; Daniela Benz; Ingmar Heijnen; Ludwig Kappos; David T Winkler
Journal:  J Neurol       Date:  2011-07-18       Impact factor: 4.849

Review 2.  The Ku complex: recent advances and emerging roles outside of non-homologous end-joining.

Authors:  Sanna Abbasi; Gursimran Parmar; Rachel D Kelly; Nileeka Balasuriya; Caroline Schild-Poulter
Journal:  Cell Mol Life Sci       Date:  2021-04-15       Impact factor: 9.261

3.  Sjogren's Syndrome and Pulmonary Disease.

Authors:  Ruben A Peredo; Scott Beegle
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku.

Authors:  Thierry Zenone; Nathalie Streichenberger; Marie Puget
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

Review 5.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

Review 6.  Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Authors:  Minoru Satoh; Monica Vázquez-Del Mercado; Edward K L Chan
Journal:  Mod Rheumatol       Date:  2009-03-10       Impact factor: 3.023

7.  The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders.

Authors:  S G Gofrit; H Yonath; M Lidar; Y Shoenfeld; S Kivity
Journal:  Clin Rheumatol       Date:  2018-02-16       Impact factor: 2.980

8.  International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.

Authors:  Katja Lakota; Gerhard G Thallinger; Snezna Sodin-Semrl; Blaz Rozman; Ales Ambrozic; Matija Tomsic; Sonja Praprotnik; Sasa Cucnik; Katjusa Mrak-Poljsak; Angela Ceribelli; Ilaria Cavazzana; Franco Franceschini; Jiri Vencovsky; Laszlo Czirják; Cecilia Varjú; Gunther Steiner; Martin Aringer; Bojana Stamenkovic; Oliver Distler; Marco Matucci-Cerinic; Tanja Kveder
Journal:  Arthritis Res Ther       Date:  2012-01-06       Impact factor: 5.156

Review 9.  Novel aspects of Sjögren's syndrome in 2012.

Authors:  Angela Tincani; Laura Andreoli; Ilaria Cavazzana; Andrea Doria; Marta Favero; Maria-Giulia Fenini; Franco Franceschini; Andrea Lojacono; Giuseppe Nascimbeni; Amerigo Santoro; Francesco Semeraro; Paola Toniati; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

10.  DNA-PK is a DNA sensor for IRF-3-dependent innate immunity.

Authors:  Brian J Ferguson; Daniel S Mansur; Nicholas E Peters; Hongwei Ren; Geoffrey L Smith
Journal:  Elife       Date:  2012-12-18       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.